Source comparison
Best BPC-157 Dosage Wound Healing 2026: Administration Method Comparison
Subcutaneous (localized) 250mcg daily 85–95% at injury site Isolated tendon/ligament injuries, localized muscle tears, post-surgical incisions 2–4 hours 2–4 weeks Highest tissue concentration for single-site injuries. Gold standard for Achilles tendinopathy, r
This comparison does not assign a generated winner or score.
- Subcutaneous (localized)
- 250mcg daily
- 85–95% at injury site
- Isolated tendon/ligament injuries, localized muscle tears, post-surgical incisions
- 2–4 hours
- 2–4 weeks
- Highest tissue concentration for single-site injuries. Gold standard for Achilles tendinopathy, rotator cuff, lateral epicondylitis
- Intramuscular (systemic)
- 500mcg daily
- 70–80% systemic
- Diffuse soft tissue trauma, multiple injury sites, post-operative recovery
- 4–6 hours
- 4–6 weeks
- Best for whole-body recovery needs. Lower peak concentration but broader distribution
- Oral
- 500–1000mcg daily
- 40–60% (first-pass loss)
- Gastric ulcers, internal mucosal healing, patients unable to self-inject
- 1–2 hours GI tract, 6–8 hours systemic
- 4–8 weeks
- Requires 2–3× parenteral dose for equivalent effect. Viable for GI-specific healing but inefficient for musculoskeletal injuries
- Intranasal (experimental)
- 200–400mcg daily
- Unknown (limited data)
- CNS-adjacent injuries (rare research use)
- Unknown
- Variable
- Insufficient clinical data for wound healing. Theoretical CNS penetration advantage not demonstrated
- Localized subcutaneous injection delivers the best BPC-157 dosage wound healing outcomes for isolated injuries. Muscle strains, tendon tears, surgical incisions. Where you can pinpoint the injury site within 2cm. Systemic intramuscular protocols make sense when multiple sites need support or the injury is diffuse (like post-marathon muscle damage). Oral administration works for gastric and intestinal healing but wastes peptide on musculoskeletal injuries due to first-pass metabolism.